Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication

World Journal of Gastroenterology

Volumn 21, Issue 32, 2015, Pages 9554-9565

  Wang, Jie ^a   Xu, Zhong Wei ^b   Liu, Shuang ^c   Zhang, Rui Yang ^a   Ding, Shan Long ^a   Xie, Xiao Meng ^d   Long, Lu ^a   Chen, Xiang Mei ^a   Zhuang, Hui ^a   Lu, Feng Min ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PENNSYLVANIA HOSPITAL   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d ZHENGZHOU UNIVERSITY   (China)

Author keywords

Antiviral therapy; cccDNA; CRISPR Cas9; Dual gRNAs; Hepatitis B

Indexed keywords

GUIDE RNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; CYTOTOXICITY TEST; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; RNA SEQUENCE; VIRUS GENOME; VIRUS REPLICATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; DNA, VIRAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; RNA, GUIDE; TRANSFECTION; VIRUS REPLICATION;

EID: 84940107277     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i32.9554     Document Type: Article

References (32)

1. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011; 31 Suppl 1: 111-116 [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x]
2. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000; 32: 139-146 [PMID: 10869302]
3. Caruntu FA, Molagic V. CccDNA persistence during natural evolution of chronic VHB infection. Rom J Gastroenterol 2005; 14: 373-377 [PMID: 16400354]
4. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897 [PMID: 15940624]
5. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684 [PMID: 16941693]
6. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-537 [PMID: 22251702 DOI: 10.1172/JCI58847]
7. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221-1228 [PMID: 24557838 DOI: 10.1126/science.1243462]
8. Deveau H, Garneau JE, Moineau S. CRISPR/Cas system and its role in phage-bacteria interactions. Annu Rev Microbiol 2010; 64: 475-493 [PMID: 20528693 DOI: 10.1146/annurev. micro.112408.134123]
9. Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science 2010; 327: 167-170 [PMID: 20056882 DOI: 10.1126/science.1179555]
10. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, Moineau S, Mojica FJ, Wolf YI, Yakunin AF, van der Oost J, Koonin EV. Evolution and classification of the CRISPRCas systems. Nat Rev Microbiol 2011; 9: 467-477 [PMID: 21552286 DOI: 10.1038/nrmicro2577]
11. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8: 2281-2308 [PMID: 24157548 DOI: 10.1038/nprot.2013.143]
12. Bi Y, Sun L, Gao D, Ding C, Li Z, Li Y, Cun W, Li Q. Highefficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog 2014; 10: e1004090 [PMID: 24788700 DOI: 10.1371/journal.ppat.1004090]
13. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013; 3: 2510 [PMID: 23974631 DOI: 10.1038/srep02510]
14. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J, Mo X, Khalili K. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 2014; 111: 11461-11466 [PMID: 25049410 DOI: 10.1073/pnas.1405186111]
15. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 2014; 3: e186 [PMID: 25137139 DOI: 10.1038/mtna.2014.38]
16. Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/ Cas9. Mol Ther Nucleic Acids 2014; 3: e216 [PMID: 25514649 DOI: 10.1038/mtna.2014.68]
17. Kennedy EM, Bassit LC, Mueller H, Kornepati AV, Bogerd HP, Nie T, Chatterjee P, Javanbakht H, Schinazi RF, Cullen BR. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 2015; 476: 196-205 [PMID: 25553515 DOI: 10.1016/j.virol.2014.12.001]
18. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007; 13: 14-21 [PMID: 17206751]
19. Wang Z, Huang Y, Wen S, Zhou B, Hou J. Hepatitis B virus genotypes and subgenotypes in China. Hepatol Res 2007; 37: S36-S41 [PMID: 17627634]
20. Nie JJ, Sun KX, Li J, Wang J, Jin H, Wang L, Lu FM, Li T, Yan L, Yang JX, Sun MS, Zhuang H. A type-specific nested PCR assay established and applied for investigation of HBV genotype and subgenotype in Chinese patients with chronic HBV infection. Virol J 2012; 9: 121 [PMID: 22716091 DOI: 10.1186/1743-422X-9-121]
21. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S, Desmond P, Locarnini SA. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 27-35 [PMID: 12500185]
22. Li WP, Li T, Yan L, Liu BM, Zhuang H. Construction of a 1.2-genome length genotype C HBV construct and study on its expression and replication in HepG2 cells. Ganzang 2008; 13: 211-215 [DOI: 10.14000/j.cnki.issn.1008-1704.2008.03.003]
23. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863 [PMID: 6286115]
24. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41: 1715-1720 [PMID: 9257747]
25. Zhong Y, Han J, Zou Z, Liu S, Tang B, Ren X, Li X, Zhao Y, Liu Y, Zhou D, Li W, Zhao J, Xu D. Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR. Clin Chim Acta 2011; 412: 1905-1911 [PMID: 21741960 DOI: 10.1016/j.cca.2011.06.031]
26. Li W, Zhao J, Zou Z, Liu Y, Li B, Sun Y, Li X, Liu S, Cai S, Yao W, Xin S, Lu F, Xu D. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection. PLoS One 2014; 9: e89046 [PMID: 24551214 DOI: 10.1371/journal.pone.0089046]
27. Hepatitis B. Fact sheet N 204 2015. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/
28. Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2: 50-57 [PMID: 15968340]
29. Kojima N, Horiike N, Michitaka K, Onji M. In situ detection of mutated hepatitis B virus in microdissected, formalin-fixed liver tissues from patients with chronic hepatitis B. J Hepatol 1999; 30: 359-365 [PMID: 10190715]
30. Chen L, Zhang Q, Yu DM, Wan MB, Zhang XX. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol 2009; 50: 895-905 [PMID: 19304333 DOI: 10.1016/j.jhep.2008.12.018]
31. Li X, Zhang J, Yang Z, Kang J, Jiang S, Zhang T, Chen T, Li M, Lv Q, Chen X, McCrae MA, Zhuang H, Lu F. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol 2014; 60: 975-984 [PMID: 24362074 DOI: 10.1016/j.jhep.2013.12.014]
32. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324 [PMID: 20228847 DOI: 10.1038/onc.2010.36]